https://www.indianpharmapost.com/indias-first-curapod-wearable-gets-class-ii-nod-for-drug-free-musculoskeletal-pain-relief-186632025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/asahi-kasei-pharma-to-move-rd-hub-to-shonan-ipark-in-2027-186712025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/enveda-launches-phase-1-trial-for-first-in-class-oral-ibd-therapy-186702025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/abbotts-volt-pfa-system-gets-fda-nod-186692025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/hansa-biopharma-submits-fda-application-for-kidney-transplant-desensitization-treatment-186682025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/niagen-bioscience-secures-full-ownership-of-key-nad-patents-in-major-ip-move-186672025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/gilead-licenses-assembly-bios-investigational-herpes-drugs-after-positive-phase-1b-data-186662025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/fda-nod-to-boehringer-ingelheims-jascayd-for-progressive-pulmonary-fibrosis-in-adults-186652025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/ipsen-acquires-simcere-zaimings-innovative-adc-sim0613-186642025-12-24T00:00:00+05:30always0.9https://www.indianpharmapost.com/neurocrines-valbenazine-fails-to-show-benefit-in-largest-dyskinetic-cerebral-palsy-trial-186722025-12-24T00:00:00+05:30always0.9